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INTRODUCTION
Urticarial vasculitis is characterized by recurrent episodes
of urticaria with biopsy evidence of leukocytoclastic vasculi-
tis (1). Although urticarial vasculitis is frequently idiopath-
ic, it has been reported to be associated with infection, malig-
nancy, certain drugs, and connective tissue diseases such as
systemic lupus erythematosus (SLE) and Sjogren’s syndrome
(2). Here, we report a case wherein urticarial vasculitis pre-
ceded the manifestations of SLE.
CASE REPORT
In August 2005, a 50-yr-old woman visited our hospital
with a 3-month history of recurrent multiple urticarial rash-
es and wheals on the face, trunk and back. These skin mani-
festations would persist for more than 24 hr and resolved with
hyperpigmentation. The patient presented with marked sw-
elling of the face and lip. Treatment with antihistaminic and
prednisolone resulted in improvement of her skin lesions, and
she thereafter received prednisolone intermittently depend-
ing on her symptom recurrence. 
After 1 yr, she visited our hospital due to a malar rash and
pitting edema of both the legs and recurrent episodes of ur-
ticaria (Fig. 1). She had not experienced dry eye or dry mouth.
Laboratory tests revealed the following findings: hemoglobin
level, 9.6 g/dL; white blood cell (WBC) count, 1,970/μ L
(neutrophils 62%); platelets, 269×103/μ L; total protein, 6.3
g/dL; albumin, 2.7 g/dL; blood urea nitrogen (BUN), 14 mg/
dL; creatinine, 1.0 mg/dL; and C-reactive protein, 1.4 mg/L.
A high titer of antinuclear antibodies (ANA) was detected
(1:640, speckled), while the test for double-stranded DNA
antibody was negative. Anti-smith, anti-Ro, and anti-La anti-
bodies were all positive.
The C3 level (28.7 mg/dL; normal range, 55-120 mg/dL),
C4 level (6.3 mg/dL; normal range, 20-50 mg/dL), CH50
level (6.7 U/mL; normal range, 23-46 U/mL ), and C1q level
(6.6 mg/dL; normal range, 10-20 mg/dL) were markedly
decreased, whereas the anti-C1q antibody level was increased
to 23.3 U/mL (normal level, <10 U/mL). The C1 esterase in-
hibitor level was normal (25 mg/dL; normal range, 6-25 mg/
dL) and cryoglobulin was not detected. The serological test
results for hepatitis B and C viruses were negative. Urinary
analysis showed protein, ++; red blood cell (RBC) count, 6-
10/high-power field (HPF); and 24-hr urine protein, 1.1 g/
day, and the creatinine clearance rate was 44.0 mL/min.
Skin biopsy revealed diffuse polymorphonuclear leukocyte
infiltration in the dermis. In particular, distinct infiltration
of neutrophils and nuclear dust was noted at the walls of small
vessels (Fig. 2). Renal biopsy revealed subepithelial and mesan-
gial immune deposits. IgG was positive along the capillary
loop, and C1q and C3 were positive in the mesangium. Renal
biopsy findings were compatible with membranous nephri-
tis (Fig. 3).
The diagnosis of SLE was established because of the pres-
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Hypocomplementemic Urticarial Vasculitis in Systemic Lupus
Erythematosus
Urticarial vasculitis is characterized clinically by urticarial skin lesions and histologi-
cally by leukocytoclastic vasculitis. Hypocomplementemic urticarial vasculitis is asso-
ciated with connective tissue diseases such as systemic lupus erythematosus (SLE).
We report a case of urticarial vasculitis that preceded manifestations of SLE.
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ence of a malar rash, proteinuria, leukopenia, high ANA titer,
and the presence of the anti-smith antibody. The patient’s
skin lesion was diagnosed as hypocomplementemic urticarial
vasculitis (HUV).
An intravenous steroid pulse (1.0 g/day×3 days) followed
by a high-dose oral steroid (1 mg/kg) were administered after
the disappearance of the vasculitic wheal and angioedema.
Hematuria and proteinuria were resolved, and mycopheno-
late mofetil (500 mg, bid) and hydroxychloroquine were added
to the therapy. However, in July 2007, the tapering of the
steroid administration was accompanied by the recurrence of
urticaria, angioedema, conjunctivitis, and episodes of abdom-
inal pain. Despite mycophenolate mofetil, the patient’s skin
lesions recurred without recurrence of proteinuria. Treatment
with prednisone and dapsone was initiated, and the urticaria
resolved. Dapsone and steroid therapy did not completely re-
lieve, but instead attenuated the urticarial vasculitic lesions. 
DISCUSSION
Urticarial vasculitis resembles urticaria, is usually painful
or nonpruritic, and typically persists for more than 24 hr (1).
The lesion can sometimes be pruritic, but is more common-
ly asymptomatic or painful. It usually resolves with hyper-
pigmentation or purpura (1).
Patients with urticarial vasculitis can be divided into two
groups, those with normal complement levels and those with
HUV (1, 2). The latter are more likely to exhibit systemic
manifestations, including constitutional symptoms (fever,
malaise, and fatigue), arthralgia, arthritis, serositis, glomeru-
lonephritis, interstitial nephritis, and Raynaud’s phenomenon
(2). Angioedema-like lesions are present in as many as 40%
of patients, frequently involving the lips, tongue, periorbital
tissue, and hands (2). Some patients have ocular inflamma-
tion like conjunctivitis and episcleritis (3).
By definition, serum complement levels are decreased in
Fig. 1. Urticarial vasculitic skin lesions on the back of the patient.
Urticarial plaques frequently persisted for more than 24 hr.
Fig. 3. Electron micrograph showed multiple global subepithelial
electron dense deposits. A neomembrane covered the deposits
and bridges the intervening basement membrane spikes. The foot
process were effaced (×7,500).
Fig. 2. Skin biopsy revealed diffuse polymorphonuclear leukocyte
infiltration in the dermis and multifocal neutrophilic and nuclear dust
infiltration at small vessel walls (H&E, ×200).186 M.Y. Her, J.Y. Song, and D.Y. Kim
HUV. Complement measurements with low C1q and C4 lev-
els and variably decreased C3 levels indicated activation of
the classical pathway. C1q precipitins were identified and were
later confirmed to be autoantibodies against C1q (anti-C1q
autoantibody) (4). Antibodies against C1q act as a diagnos-
tic marker for HUV (1, 3). However, they are not specific to
HUV and have also been observed in SLE. Anti-C1q antibod-
ies were detected in 30% of patients with SLE and 80% of
SLE patients with glomerulonephritis (5). This patient also
showed decreased levels of C3, C4, CH50, and C1q and in-
creased levels of the anti-C1q antibody. She simultaneously
exhibited HUV and SLE with glomerulonephritis, both of
which are possible causes of decreased complement and the
presence of anti-C1q antibody.
In most cases, the histological findings of urticarial vasculi-
tis include a majority of features of completely developed le-
ukocytoclastic vasculitis (2). Direct immunofluoroscence of
skin biopsy samples from HUV patients usually show im-
munoglobulin and complement deposition in a granular pat-
tern in and around the blood vessels of the upper dermis and
the basement membrane (2).
This patient exhibited typical findings of HUV. She expe-
rienced recurrent urticaria with vasculitis, episodes of angi-
oedema and eye inflammation, and the serum anti-C1q auto-
antibody was positive. She also fulfilled the criteria of SLE with
urticarial lesions that persisted for more than 24 hr and left
a brownish pigmentation, which is different from true ur-
ticaria.
The clinicopathologic features of HUV are similar to those
of SLE. Some authors suggest the possible progression of HUV
to SLE, and others have defined HUV as an SLE subtype (6,
7). At times, a hypocomplementemic patient initially diag-
nosed with an idiopathic HUV has an underlying disease such
as SLE or Sjogren’s syndrome (1). HUV is associated with SLE
in most cases (54%), but normocomplementemic urticarial
vasculitis is not strongly associated with SLE (2%) (8). This
patient suffered from urticaria and angioedema for several
years. Serum complement levels were not checked initially,
and a skin biopsy was performed 1 yr after disease onset; the
results revealed urticarial vasculitis. However, in this case, we
assume that urticarial vasculitis was the presenting symptom
of SLE.
HUV has been reported to be recurrent in some patients,
with an unpredictable response to therapy (1, 2). Intravenous
methylprednisolone and cyclophosphamide or high-dose oral
corticosteroids, colchicines, dapsone, hydroxychloroquine, and
low-dose methotrexate have all been reported to be effective
treatments (1, 2, 9). In this patient, the skin lesions resolved
initially with steroids, but were subsequently refractory to
treatment. We increased the dose of steroid and added dap-
sone. Mycophenolate mofetil, which was administered for lu-
pus nephritis, did not affect urticarial vasculitis.
In conclusion, if urticarial vasculitis is suspected, lesional
skin should be biopsied. When histological findings suggest
leukocytoclastic vasculitis, complement levels should be mea-
sured. Although HUV resembles SLE both clinically and im-
munologically, an association HUV and SLE is not clear yet.
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